Atlanta, GA — May 6, 2026 — Andson Biotech will exhibit at the 73rd American Society for Mass Spectrometry (ASMS) Conference, taking place May 31–June 4, 2026, in San Diego, California. At Booth 715, the company will showcase its DynaChip X1TM platform, highlighting how automated microfluidic online buffer exchange is transforming native mass spectrometry (nMS) and charge detection mass spectrometry (CDMS) workflows across drug discovery, biotherapeutics characterization, and bioprocess monitoring.
Native MS provides powerful, label-free insights into biomolecular structure, interactions, and higher-order complexes, yet adoption has been hindered by manual buffer exchange, complex nanoESI workflows, and low throughput. The DynaChip X1TM platform addresses these barriers with rapid, automated online buffer exchange and integrated, reproducible nanoelectrospray ionization, enabling sample-to-result workflows in under 15 minutes while preserving native conformations.
Designed for versatility, DynaChipTM supports a broad range of analytes—from proteins and monoclonal antibodies to mRNA and adeno-associated viruses (AAVs)—while maintaining non-covalent interactions and enabling extended acquisition times needed for advanced techniques such as charge detection MS (CDMS) measurements. The platform’s tangential flow filtration and microdialysis approach enables efficient desalting, removing of metabolites, detergents, and interferents without compromising structural integrity.
At ASMS 2026, Andson will highlight new workflows for high-throughput protein–ligand screening, where DynaChipTM eliminates manual desalting and removes non-binding ligands during analysis while preserving protein-ligand complexes. This enables label-free detection of binding interactions in physiological buffers and supports scalable screening workflows for drug discovery.
The company will also showcase expanded capabilities for direct analysis from complex biological matrices, including cell culture and crude spent media. By removing matrix components that suppress ionization, DynaChipTM enables untargeted, label-free analysis of secreted factors, supporting real-time, in-process monitoring of cell and gene therapy manufacturing. In collaborative studies, the platform has also demonstrated at-line monitoring of monoclonal antibody production, capturing glycosylation and higher-order structural changes across bioprocess conditions in approximately 15 minutes.
Additional studies highlight improved recovery and sensitivity for complex biotherapeutics, including charge variant and antibody–drug conjugate (ADC) characterization, by eliminating sample loss associated with traditional offline cleanup methods.
Andson Biotech will be represented on multiple posters and a talk demonstrating DynaChipTM-enabled innovation:
- Oral 9:10 am Room 6DE (June 1): Scalable Native Mass Spectrometry Enabled by Online Tangential Flow Filtration
- Poster 189 (June 1): A Quantitative Comparison of Automated Desalting Methods for the High-Throughput Collision Induced Unfolding Analysis of Biotherapeutics Direct from Formulation
- Poster 372 (June 3): Enabling Routine Native Mass Spectrometry for Diverse Biotherapeutics with Automated Online Buffer Exchange
- Poster 655 (June 3): A Native Mass Spectrometry Protein-Ligand Screening Workflow Enabled by Automated Microfluidic Online Buffer Exchange
- Poster 052 (June 4): The Effect of Different Mobilizer Additives on Sample Stability and Subsequent MS Analysis with DynaChip X1 Online Buffer Exchange
- Poster 500 (June 4): At-line monitoring of biotherapeutic production and quality, using native ion mobility-mass spectrometry directly from crude spent media
- Poster 508 (June 4): Towards In-Process Monitoring of Cell Therapies: Online Buffer Exchange for Cell Culture Media Analysis
- Poster 509 (June 4): Online Buffer Exchange with Nanoflow Infusion Streamlining Ensemble and Charge Detection Native Mass Spectrometry
Attendees are invited to visit Booth 715 for instrument demonstration and to learn how Andson Biotech is enabling simplified sample preparation and streamlined discoveries through automated native MS workflows.
About Andson Biotech
Andson Biotech develops innovative microfluidic technologies that simplify sample preparation and enable advanced analytical workflows, helping researchers and pharmaceutical companies accelerate discovery and advance next-generation biotherapeutics.
